ALEC

Alector, Inc.

4.67 USD
-0.01 (-0.21%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Alector, Inc. stock is down -14.15% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 5 June’s closed higher than May.

About Alector, Inc.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the. treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases.